Biocon Q2FY26: Revenue up 20%, EBITDA up 29%, Net Profit up 428%
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts more than Nifty Midcap 150 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon Q2FY26: Operating revenue Rs 4,296 Cr, up 20% YoY. EBITDA Rs 928 Cr, up 29%; margins expanded to 21% from 20%. PBT before exceptional items Rs 183 Cr, up 153%. Reported net profit Rs 85 Cr versus a Rs 16 Cr loss last year. Biosimilars grew 25%, Generics 24%. Company settled structured debt with Goldman Sachs and Kotak via QIP proceeds, strengthening the balance sheet.
Strong quarter with broad-based growth, margin expansion, and debt reduction; H1FY26 PAT still down 82% YoY due to prior year one-time gains.